FIRST AMENDMENT TO THE MUTUAL NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 14th, 2018 • Glaxosmithkline PLC • Pharmaceutical preparations
This First Amendment to the Mutual Non-Disclosure Agreement (“the Agreement”) dated the 8th day of August 2018 (this “First Amendment”) is made and entered into as of the 8th day of November 2018 (“Effective Date”), by and between TESARO, Inc. (together with its direct and indirect subsidiaries and affiliates, “TESARO”) at 1000 Winter Street, Waltham, MA 02451 (“Company”) and GlaxoSmithKline LLC, with an address of 1250 South Collegeville Road, Collegeville, PA 19426 (together with its direct and indirect subsidiaries and affiliates, “Company”). Capitalized terms used in this First Amendment but not defined below or elsewhere in this First Amendment shall have the meanings set forth in the Agreement. In consideration of the mutual promises and covenants set forth herein, the sufficiency of which is hereby acknowledged, the Parties agree as follows:
MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • December 14th, 2018 • Glaxosmithkline PLC • Pharmaceutical preparations • Delaware
This MUTUAL NON-DISCLOSURE AGREEMENT is made and entered into as of this 8th day of August, 2018 (the “Effective Date”), between TESARO, Inc. (together with its direct and indirect subsidiaries and affiliates, “TESARO”), located at 1000 Winter Street, Waltham, MA 02451, and GlaxoSmithKline LLC , with an address of 1250 South Collegeville Road, Collegeville, PA 19426 (together with its direct and indirect subsidiaries and affiliates, “Company”). (TESARO and Company may be referred to, collectively, in this Agreement as the “Parties”, and, individually, as a “Party”).
November 23, 2018Letter Agreement • December 14th, 2018 • Glaxosmithkline PLC • Pharmaceutical preparations • Delaware
3-WAY NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 14th, 2018 • Glaxosmithkline PLC • Pharmaceutical preparations • Delaware
This 3-WAY NON-DISCLOSURE AGREEMENT is made and entered into as of this 15th day of November, 2018 (the “Effective Date”), among TESARO, Inc. (“TESARO”), located at 1000 Winter Street, Waltham, MA 02451, GlaxoSmithKline LLC, located at 1250 South Collegeville Road, Collegeville, PA 19426 (“GSK”), and Ajinomoto Althea, Inc.DBA Ajinomoto Bio-Pharma Services(“ABPS”), located at 11040 Roselle Street, San Diego, CA 92121 (“APBS”). TESARO, GSK and Althea may be referred to, collectively, in this Agreement as the “Parties”, and, individually, as a “Party”.
